Their product, the ELAD System, is an extracorporeal bio-artificial liver therapy that aims to regenerate the patient's liver or stabilize them until transplant. ELAD has shown potential in increasing survival rates and has received orphan designation in the US and Europe. The company is currently conducting Phase III clinical trials for various liver failure conditions.